AFQ056 + Placebo

Phase 2Terminated

0 views this week 0 watching💤 Quiet

Interest: 27/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Huntington's Disease

Conditions

Huntington's Disease, Chorea

Trial Timeline

Nov 1, 2009 → —

NCT ID

NCT01019473

About AFQ056 + Placebo

AFQ056 + Placebo is a phase 2 stage product being developed by Novartis for Huntington's Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT01019473. Target conditions include Huntington's Disease, Chorea.

What happened to similar drugs?

1 of 2 similar drugs in Huntington's Disease were approved

Approved (1) Terminated (1) Active (0)

✅TetrabenazineLundbeckApproved

❌SAGE-718Supernus PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (11)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04771143	Phase 1	Withdrawn	Jul 21, 2021	Jan 3, 2022	Cocaine Use Disorder
NCT03242928	Phase 2	Completed	Dec 4, 2017	Dec 16, 2019	Cocaine-related Disorder
NCT02920892	Phase 2	Completed	Aug 17, 2017	May 17, 2022	Fragile X Syndrome
NCT01813019	Phase 2	Terminated	Nov 1, 2013	Nov 1, 2014	Patient Diagnosed With OCD and Resistant to SSRI Treatment
NCT01491529	Phase 2	Completed	Apr 1, 2012	Apr 1, 2013	Dyskinesias
NCT01385592	Phase 2	Completed	Nov 1, 2011	Sep 1, 2012	Dyskinesias
NCT01357239	Phase 2	Completed	May 1, 2011	Jan 1, 2014	Fragile X Syndrome
NCT01253629	Phase 2	Completed	Nov 1, 2010	Aug 1, 2013	Fragile X Syndrome
NCT01019473	Phase 2	Terminated	Nov 1, 2009	—	Huntington's Disease
NCT00888004	Phase 2	Completed	Mar 1, 2009	—	Parkinson's Disease
NCT00582673	Phase 2	Completed	Oct 1, 2007	—	Parkinson's Disease

Competing Products

15 competing products in Huntington's Disease

See all competitors

Product	Company	Stage	Hype Score
RO7234292 (RG6042)	Roche	Phase 2	35
RG6496 + Placebo	Roche	Phase 1	36
PF-02545920 + PF-02545920	Pfizer	Phase 2	35
20 mg BID of PF-02545920	Pfizer	Phase 2	27
PF-02545920 + Placebo + PF-02545920 + Placebo	Pfizer	Phase 2	35
ALN-HTT02 + Placebo	Alnylam Pharmaceuticals	Phase 1	33
Tetrabenazine	Lundbeck	Approved	36
BN82451B + Placebo	Ipsen	Phase 2	24
ISIS 443139 10 mg + ISIS 443139 30 mg + ISIS 443139 60 mg + ISIS 443139 90 mg + ISIS 443139 120 mg	Ionis Pharmaceuticals	Phase 1/2	29
WVE-120102 + Placebo	WaVe Life Sciences	Phase 1/2	18
WVE-120101 + Placebo	WaVe Life Sciences	Phase 1/2	18
SAGE-718	Supernus Pharmaceuticals	Phase 3	26
SAGE-718 + Placebo	Supernus Pharmaceuticals	Phase 2	29
OMS643762 + Placebo	Omeros Corporation	Phase 2	21
VX15/2503 + Placebo	Vaccinex	Phase 2	25